nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—MTOR—forebrain—attention deficit hyperactivity disorder	0.0734	0.122	CbGeAlD
Pimecrolimus—FKBP1A—Alpha-synuclein signaling—STUB1—attention deficit hyperactivity disorder	0.0677	0.17	CbGpPWpGaD
Pimecrolimus—FKBP1A—TGF-beta receptor signaling activates SMADs—STUB1—attention deficit hyperactivity disorder	0.066	0.166	CbGpPWpGaD
Pimecrolimus—FKBP1A—forebrain—attention deficit hyperactivity disorder	0.066	0.11	CbGeAlD
Pimecrolimus—MTOR—cardiovascular system—attention deficit hyperactivity disorder	0.062	0.103	CbGeAlD
Pimecrolimus—FKBP1A—cardiovascular system—attention deficit hyperactivity disorder	0.0558	0.0928	CbGeAlD
Pimecrolimus—FKBP1A—midbrain—attention deficit hyperactivity disorder	0.0436	0.0725	CbGeAlD
Pimecrolimus—MTOR—nervous system—attention deficit hyperactivity disorder	0.0398	0.0663	CbGeAlD
Pimecrolimus—MTOR—central nervous system—attention deficit hyperactivity disorder	0.0383	0.0638	CbGeAlD
Pimecrolimus—MTOR—cerebellum—attention deficit hyperactivity disorder	0.0375	0.0623	CbGeAlD
Pimecrolimus—FKBP1A—nervous system—attention deficit hyperactivity disorder	0.0358	0.0596	CbGeAlD
Pimecrolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—STUB1—attention deficit hyperactivity disorder	0.0353	0.0885	CbGpPWpGaD
Pimecrolimus—FKBP1A—central nervous system—attention deficit hyperactivity disorder	0.0345	0.0574	CbGeAlD
Pimecrolimus—FKBP1A—cerebellum—attention deficit hyperactivity disorder	0.0337	0.0561	CbGeAlD
Pimecrolimus—MTOR—brain—attention deficit hyperactivity disorder	0.0304	0.0506	CbGeAlD
Pimecrolimus—FKBP1A—Alpha-synuclein signaling—SLC6A3—attention deficit hyperactivity disorder	0.0286	0.0717	CbGpPWpGaD
Pimecrolimus—FKBP1A—brain—attention deficit hyperactivity disorder	0.0274	0.0455	CbGeAlD
Pimecrolimus—FKBP1A—Spinal Cord Injury—RTN4—attention deficit hyperactivity disorder	0.0192	0.0481	CbGpPWpGaD
Pimecrolimus—MTOR—FSH signaling pathway—BDNF—attention deficit hyperactivity disorder	0.0146	0.0367	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—SNAP23—attention deficit hyperactivity disorder	0.0124	0.0312	CbGpPWpGaD
Pimecrolimus—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.0117	0.0195	CbGeAlD
Pimecrolimus—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.0113	0.0187	CbGeAlD
Pimecrolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.0105	0.0262	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—STUB1—attention deficit hyperactivity disorder	0.0101	0.0253	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—BDNF—attention deficit hyperactivity disorder	0.008	0.0201	CbGpPWpGaD
Pimecrolimus—MTOR—HSF1-dependent transactivation—EP300—attention deficit hyperactivity disorder	0.00772	0.0194	CbGpPWpGaD
Pimecrolimus—FKBP1A—Role of Calcineurin-dependent NFAT signaling in lymphocytes—EP300—attention deficit hyperactivity disorder	0.00669	0.0168	CbGpPWpGaD
Pimecrolimus—FKBP1A—TGF-beta Receptor Signaling—EP300—attention deficit hyperactivity disorder	0.00669	0.0168	CbGpPWpGaD
Pimecrolimus—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00561	0.0141	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00544	0.0136	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—RTN4—attention deficit hyperactivity disorder	0.00531	0.0133	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular response to heat stress—EP300—attention deficit hyperactivity disorder	0.00499	0.0125	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—SNAP25—attention deficit hyperactivity disorder	0.00486	0.0122	CbGpPWpGaD
Pimecrolimus—MTOR—IFN-gamma pathway—EP300—attention deficit hyperactivity disorder	0.00452	0.0113	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00384	0.00962	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.00379	0.00951	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—STUB1—attention deficit hyperactivity disorder	0.00353	0.00884	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—STUB1—attention deficit hyperactivity disorder	0.00351	0.0088	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00315	0.0079	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.00278	0.00698	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00246	0.00616	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00244	0.00611	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00221	0.00554	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—STUB1—attention deficit hyperactivity disorder	0.00214	0.00536	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00211	0.0053	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00207	0.00519	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00203	0.00509	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—STUB1—attention deficit hyperactivity disorder	0.00197	0.00495	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00177	0.00444	CbGpPWpGaD
Pimecrolimus—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00172	0.00432	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SNAP25—attention deficit hyperactivity disorder	0.00166	0.00417	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00165	0.00415	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—POLR3A—attention deficit hyperactivity disorder	0.00162	0.00406	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00143	0.0036	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00138	0.00347	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00125	0.00314	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00119	0.00298	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00117	0.00292	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00116	0.00292	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00114	0.00286	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00113	0.00283	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.00111	0.00278	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.0011	0.00275	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—EP300—attention deficit hyperactivity disorder	0.00106	0.00265	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00102	0.00256	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SNAP25—attention deficit hyperactivity disorder	0.000936	0.00235	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000922	0.00231	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000915	0.00229	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000909	0.00228	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000807	0.00202	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000715	0.00179	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000705	0.00177	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000656	0.00164	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000635	0.00159	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000624	0.00156	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000616	0.00155	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000574	0.00144	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000566	0.00142	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EP300—attention deficit hyperactivity disorder	0.000541	0.00136	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000402	0.00101	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000379	0.00095	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000377	0.000945	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EP300—attention deficit hyperactivity disorder	0.00033	0.000826	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EP300—attention deficit hyperactivity disorder	0.000304	0.000763	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00026	0.000652	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00026	0.000652	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000256	0.000642	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000238	0.000596	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000213	0.000534	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000208	0.000521	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000198	0.000496	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	0.000158	0.000395	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000156	0.000392	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	6.76e-05	0.000169	CbGpPWpGaD
